The cost-utility of sequential adjuvant trastuzumab in women with Her2/Neu-positive breast cancer: an analysis based on updated results from the HERA Trial

Chris Skedgel; Daniel Rayson; Tallal Younis

doi:10.1111/j.1524-4733.2009.00511.x

The cost-utility of sequential adjuvant trastuzumab in women with Her2/Neu-positive breast cancer: an analysis based on updated results from the HERA Trial

Chris Skedgel, Daniel Rayson, Tallal Younis

Research output: Contribution to journal › Article › peer-review

32 Citations (Scopus)

Abstract

The efficacy of sequential adjuvant trastuzumab (aTZ) after chemotherapy in women with early-stage human epidermal growth factor-2 (HER2/neu)-positive breast cancer reported by the updated Herceptin Adjuvant (HERA) trial appears less favorable than originally reported. Based on these updated results, we estimated the cost-utility (CU) of sequential aTZ relative to chemotherapy alone in terms of incremental cost per quality-adjusted life-year (QALY) gained.

Original language	English
Pages (from-to)	641-648
Number of pages	8
Journal	Value in Health
Volume	12
Issue number	5
DOIs	https://doi.org/10.1111/j.1524-4733.2009.00511.x
Publication status	Published - Jul 2009

Keywords

breast cancer
cost-utility
net-benefits
relative risk
trastuzumab

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/j.1524-4733.2009.00511.x

Cite this

@article{97e56773e4ef45a381a5442a670fec08,

title = "The cost-utility of sequential adjuvant trastuzumab in women with Her2/Neu-positive breast cancer: an analysis based on updated results from the HERA Trial",

abstract = "The efficacy of sequential adjuvant trastuzumab (aTZ) after chemotherapy in women with early-stage human epidermal growth factor-2 (HER2/neu)-positive breast cancer reported by the updated Herceptin Adjuvant (HERA) trial appears less favorable than originally reported. Based on these updated results, we estimated the cost-utility (CU) of sequential aTZ relative to chemotherapy alone in terms of incremental cost per quality-adjusted life-year (QALY) gained.",

keywords = "breast cancer, cost-utility, net-benefits, relative risk, trastuzumab",

author = "Chris Skedgel and Daniel Rayson and Tallal Younis",

year = "2009",

month = jul,

doi = "10.1111/j.1524-4733.2009.00511.x",

language = "English",

volume = "12",

pages = "641--648",

journal = "Value in Health",

issn = "1098-3015",

publisher = "Elsevier",

number = "5",

}

TY - JOUR

T1 - The cost-utility of sequential adjuvant trastuzumab in women with Her2/Neu-positive breast cancer

T2 - an analysis based on updated results from the HERA Trial

AU - Skedgel, Chris

AU - Rayson, Daniel

AU - Younis, Tallal

PY - 2009/7

Y1 - 2009/7

N2 - The efficacy of sequential adjuvant trastuzumab (aTZ) after chemotherapy in women with early-stage human epidermal growth factor-2 (HER2/neu)-positive breast cancer reported by the updated Herceptin Adjuvant (HERA) trial appears less favorable than originally reported. Based on these updated results, we estimated the cost-utility (CU) of sequential aTZ relative to chemotherapy alone in terms of incremental cost per quality-adjusted life-year (QALY) gained.

AB - The efficacy of sequential adjuvant trastuzumab (aTZ) after chemotherapy in women with early-stage human epidermal growth factor-2 (HER2/neu)-positive breast cancer reported by the updated Herceptin Adjuvant (HERA) trial appears less favorable than originally reported. Based on these updated results, we estimated the cost-utility (CU) of sequential aTZ relative to chemotherapy alone in terms of incremental cost per quality-adjusted life-year (QALY) gained.

KW - breast cancer

KW - cost-utility

KW - net-benefits

KW - relative risk

KW - trastuzumab

U2 - 10.1111/j.1524-4733.2009.00511.x

DO - 10.1111/j.1524-4733.2009.00511.x

M3 - Article

C2 - 19490562

VL - 12

SP - 641

EP - 648

JO - Value in Health

JF - Value in Health

SN - 1098-3015

IS - 5

ER -